Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice
Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani, Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani
Abstract
Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences. At present, the only recommended treatment of CCM is surgical. Because surgery is often not applicable, pharmacological treatment would be highly desirable. We describe here a murine model of the disease that develops after endothelial-cell-selective ablation of the CCM3 gene. We report an early, cell-autonomous, Wnt-receptor-independent stimulation of β-catenin transcription activity in CCM3-deficient endothelial cells both in vitro and in vivo and a triggering of a β-catenin-driven transcription program that leads to endothelial-to-mesenchymal transition. TGF-β/BMP signaling is then required for the progression of the disease. We also found that the anti-inflammatory drugs sulindac sulfide and sulindac sulfone, which attenuate β-catenin transcription activity, reduce vascular malformations in endothelial CCM3-deficient mice. This study opens previously unidentified perspectives for an effective pharmacological therapy of intracranial vascular cavernomas.
Keywords: cerebral cavernous malformation; endothelial cells; sulindac metabolites; vascular pathology; β-catenin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Source: PubMed
Prochains essais cliniques
-
Shirley Ryan AbilityLabKiwanis Neurological Research FoundationRecrutementTraumatisme crânien TBIÉtats-Unis
-
University of ChicagoNational Heart, Lung, and Blood Institute (NHLBI)Pas encore de recrutementThromboembolie veineuse | Chirurgie du pelvis | Chirurgie du cancer de l'abdomenÉtats-Unis
-
Fundacion para la Investigacion Biomedica del Hospital...Hospital Universitario La FeRecrutement
-
Lumetry Diagnostics GmbHKarl Landsteiner Institute for Lung Research and Pneumological Oncology; Klinik...Pas encore de recrutementMaladie pulmonaire obstructive chronique | HypercapnieL'Autriche
-
Beijing Suncadia Pharmaceuticals Co., LtdRecrutementLa maladie d'AlzheimerChine
-
IpsenPas encore de recrutementCancer de la prostate
-
Xiangya Hospital of Central South UniversityPas encore de recrutementPsoriasis en plaques | DyslipidémieChine
-
Halic UniversityPas encore de recrutementQualité du sommeil | Intervention diététique | Stress perçu | Brouillard cérébralTurquie (Türkiye)
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPas encore de recrutementCancer du sein métastatique | Cancer du sein à récepteurs hormonaux positifs | Cancer du sein HER2-faibleChine
-
The 108 Military Central HospitalVietnam Military Medical University; Thanh Phuong Co., LtdPas encore de recrutementChoc septique | Lésion rénale aiguëViêt Nam
-
University Hospital, MontpellierPas encore de recrutementHémiparésie | Spasticité | Spasticité des membres supérieursFrance
-
Kasr El Aini HospitalRecrutementMastite granulomateuse idiopathiqueEgypte